| Politician | Action | Description | Traded |
|---|---|---|---|
| Sell | ACADIA PHARMACEUTICALS INC C | Feb 5, 2026 | |
| Sell | Academy Sports and Outdoors | Feb 6, 2023 | |
| Sell | ACADIA Pharmaceuticals Inc. | Jun 16, 2022 | |
| Buy | ACADIA PHARMACEUTICALS INC C | Aug 23, 2021 | |
| Sell | ACADIA Pharmaceuticals Inc. | Sep 8, 2020 | |
| Sell | ACTIVISION BLIZZARD, INC. CM | Nov 13, 2018 | |
| Sell | ACADIA PHARMACEUTICALS, INC. | Apr 3, 2018 | |
| Buy | ACADIA PHARMACEUTICALS INC C | Apr 3, 2018 | |
| Sell | ACADIA PHARMACEUTICALS INC C | Nov 30, 2017 |
This page tracks congressional stock trading activity in ACADIA Pharmaceuticals Inc. (ACAD) in the Healthcare sector. Disclosed Capitol has indexed 9 disclosed congressional trades involving ACAD. Every trade is sourced from official STOCK Act financial disclosure filings — the same primary records the Senate and House are required to publish. The full trade list with politician names, transaction types, amount ranges, and disclosure dates is below, alongside cross-references to any related lobbying activity, federal contracts, and committee assignments.
As of March 2026 — Disclosed Capitol has tracked 9 disclosed congressional trades in ACADIA Pharmaceuticals Inc. (ACAD) — 6:2 sell-heavy ratio — led by Ro Khanna (D).
| Date | Politician | Party | Action | Amount |
|---|---|---|---|---|
| Feb 5, 2026 | Ro Khanna | D | Sell | $1,001 - $15,000 |
| Feb 6, 2023 | Eric Burlison | R | Sale | $1,001 - $15,000 |
| Jun 16, 2022 | Christopher L. Jacobs | R | Sale | $1,001 - $15,000 |
| Aug 23, 2021 | Ro Khanna | D | Purchase | $1,001 - $15,000 |
| Sep 8, 2020 | Christopher L. Jacobs | R | Sale | $1,001 - $15,000 |
| Nov 13, 2018 | Ro Khanna | D | Sale | $1,001 - $15,000 |
| Apr 3, 2018 | Ro Khanna | D | Sale | $1,001 - $15,000 |
| Apr 3, 2018 | Ro Khanna | D | Purchase | $1,001 - $15,000 |
| Nov 30, 2017 | Ro Khanna | D | Sale | $1,001 - $15,000 |
Across the 9 disclosed congressional trades in ACADIA Pharmaceuticals Inc. (ACAD), members of Congress have reported 2 buys and 6 sells. The average 30-day alpha vs. the S&P 500 is -3.72%.
For fiscal year 2025, ACADIA Pharmaceuticals Inc. reported revenue of $1.07B and net income of $391.0M, per SEC filings.
Most recent reported quarter: Q2 FY2026 — revenue $308.0M, net income $31.5M.
Figures come from SEC financial statement filings. The full annual and quarterly statement history is in the Financials tab above.